NCRNAP: Study of Peripheral Blood Non-coding RNAs as Diagnosis and Prognosis Biomarker for Acute Pancreatitis

Sponsor
Changhai Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT02602808
Collaborator
(none)
1,097
3
36
365.7
10.2

Study Details

Study Description

Brief Summary

It is important to identify patients with acute pancreatitis who are at risk for developing persistent organ failure early in the course of disease. The investigators evaluated whether peripheral blood non-coding RNAs, including microRNAs and long noncoding RNA (lncRNA), could serve as a good marker for detection of acute pancreatitis with persistent organ failure at early phase.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Acute pancreatitis is a sudden inflammation of the pancreas. It can have severe complications and high mortality despite treatment. While mild cases are often successfully treated with conservative measures, such as fasting and aggressive intravenous fluid rehydration, severe cases may require admission to the intensive care unit or even surgery to deal with complications of the disease process. The diagnosis of severe acute pancreatitis at an early phase remain a major challenge for clinicians.

    Therefore, many biologic markers have been studied in an effort to improve the diagnostic rate and determine the severity of acute pancreatitis but with disappointing results. Non-coding RNAs, including microRNAs and long noncoding RNA (lncRNA), have recently been validated to stably exist in peripheral blood. Several publications showed that it may serve as potential markers for various diseases, including cancer and inflammation. Our current study evaluated whether and which kind of non-coding RNAs could serve as good markers for severe acute pancreatitis.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    1097 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Study of Peripheral Blood Non-coding RNAs as Diagnosis and Prognosis Biomarker for Acute Pancreatitis
    Actual Study Start Date :
    Dec 1, 2015
    Actual Primary Completion Date :
    Dec 1, 2018
    Actual Study Completion Date :
    Dec 1, 2018

    Arms and Interventions

    Arm Intervention/Treatment
    Severe acute pancreatitis group

    Severe acute pancreatitis is characterised by persistent organ failure.

    Moderately severe acute pancreatitis

    Moderately severe acute pancreatitis is characterised by the presence of transient organ failure or local or systemic complications in the absence of persistent organ failure.

    Mild acute pancreatitis

    Mild acute pancreatitis is characterised by the absence of organ failure and the absence of local or systemic complications.

    post-ERCP pancreatitis

    Patients with new onset of epigastric pain, an increase in pancreatic enzymes of at least three times the upper limit of the normal range within 24 hours after ERCP, and hospitalization for at least 2 nights.

    Outcome Measures

    Primary Outcome Measures

    1. The level of non-coding RNAs in peripheral blood [At admission]

      RNA quantification after extraction using RT-PCR

    Secondary Outcome Measures

    1. serum urea nitrogen [At admission]

      serum urea nitrogen quantification

    2. serum creatinine [At admission]

      serum creatinine quantification

    3. APACHE II score at admission [At admission]

      APACHE II score determined by Temperature, MAP, heart rate, respiratory rate, Pao2, arterial pH, HCO3, sodium, potassium, creatinine, hematocrit, WBC, Glasgow Coma Score, age, chronic health points

    4. BISAP score at admission [At admission]

      BISAP socre determined by BUN (>25 mg/dL), impaired mental status (Glasgow Coma Score <15), SIRS (≥2), age (>60 y), pleural effusion

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients who was diagnosed acute pancreatitis

    • Male or female

    • 18 Years and older

    • written informed consent

    Exclusion Criteria:
    • Symptoms of acute pancreatitis present for more than 72 hours

    • Age under 18 years

    • Pregnancy

    • patients unable to consent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Linyi People's Hospital Linyi Shandong China
    2 Changhai Hospital, Second Military Medical University Shanghai China 200433
    3 Department of Gastroenterology, Shanghai First People's Hospital Shanghai China 200433

    Sponsors and Collaborators

    • Changhai Hospital

    Investigators

    • Principal Investigator: Zhaoshen Li, MD, Changhai Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Zhaoshen Li, Director of gastroenterology department, Changhai Hospital
    ClinicalTrials.gov Identifier:
    NCT02602808
    Other Study ID Numbers:
    • Pancreatitis Markers
    First Posted:
    Nov 11, 2015
    Last Update Posted:
    Sep 9, 2019
    Last Verified:
    Sep 1, 2019
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Zhaoshen Li, Director of gastroenterology department, Changhai Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 9, 2019